Clinical factors and biomarkers in ovarian tumors development

Romanian Journal of Morphology and Embryology

Volumn 49, Issue 3, 2008, Pages 327-338

  Vrabie, Camelia Doina ^a,b,c   Petrescu, Angela ^a   Waller, Maria ^a   Dina, I ^b,c  

^a NATIONAL INSTITUTE FOR RESEARCH AND DEVELOPMENT IN MICROTECHNOLOGIES   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c 'Sfantul Ioan' Emergency Hospital   (Romania)

Author keywords

Immunohistochemistry; Ovarian carcinomas; Prognosis and screening markers

Indexed keywords

TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARCINOMA; DISEASE COURSE; FEMALE; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS; RISK FACTOR;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARCINOMA; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 58149180951     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Scully R. E., NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer, JAMA, 1995, 273(6):491-497.
2. Scully R. E. (ed), WHO International Histological Classification of Tumors. Histological typing of ovarian tumors, World Health Organization, Geneva, 1999.
3. th edition, Springer Verlag, New York, 2002, 791-904.
4. International Agency for Research on Cancer, IARC monographs on the evaluation of carcinogenic risk to humans. Hormonal contraception and postmenopausal hormonal therapy, vol. 72, IARC Press, Lyon, 1999.
5. Royar J., Becher H., Chang-Claude J., Low-dose oral contraceptives: protective effect on ovarian cancer risk, Int J Cancer, 2001, 95(6):370-374.
6. Riman T., Dickman P. W., Nilsson S., Correia N., Nordlinder H., Magnusson C. M., Weiderpass E., Persson I. R., Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women, J Natl Cancer Inst, 2002, 94(7):497-504.
7. Cleton-Jansen A. M., Collins N., Lakhani S. R., Weissenbach J., Devilee P., Cornelisse C. J., Stratton M. R., Loss of heterozygosity in sporadic breast tumor at the BRCA2 locus on chromosome 13q12-q13, Br J Cancer, 1995, 72(5):1241-1244.
8. Fairfield K. M., Hankinson S. E., Rosner B. A., Hunter D. J., Colditz G. A., Willett W. C., Risk of ovarian carcinoma and consumption of vitamins A, C and E and specific carotenoids: a prospective analysis, Cancer, 2001, 92(9):2318-2326.
9. Lerman C., Hughes C., Lemon S. J., Main D., Snyder C., Durham C., Narod S., Lynch H. T., What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing, J Clin Oncol, 1998, 16(5):1650-1654.
10. Lipkus I. M., Klein W. M., Rimer B. K., Communicating breast cancer risks to women using different formats, Cancer Epidemiol Biomarkers Prev, 2001, 10(8):895-898
11. Panet A., Khorana H. G., Studies on polynucleotides. The linkage of deoxyribopolynucleotide templates to cellulose and its use in their replication, J Biol Chem, 1974, 249(16):5213-5221.
12. Górski B., Jakubowska A., Huzarski T., Byrski T., Gronwald J., Grzybowska E., Mackiewicz A., Stawicka M., Bebenek M., Sorokin D., FiszerMaliszewska Ł., Haus O., Janiszewska H., Niepsuj S., Góźdź S., Zaremba L., Posmyk M., Płuzańska M., Kilar E., Czudowska D., Waśko B., Miturski R., Kowalczyk J. R., Urbański K., Szwiec M., Koc J., Debniak B., Rozmiarek A., Debniak T., Cybulski C., Kowalska E., TołoczkoGrabarek A., Zajaczek S., Menkiszak J., Medrek K., Masojć B., Mierzejewski M., Narod S. A., Lubiński J., A high proportion of founder BRCA1 mutations in Polish breast cancer families, Int J Cancer, 2004, 110(5):683-686.
13. Thorlacicus S., Olafsdottir G., Tyrggvadottir L. A., Neuhausen S., Jonasson J. G., Tavtigian S. V., Tulinius H., Ogmundsdottir H. M., Eyfjörd J. E., A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes, Nat Genet, 1996, 13(1):117-119.
14. Gayther S. A., Russell P., Harrington P., Antoniou A. C., Easton D. F., Ponder B. A., The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes, Am J Hum Genet, 1999, 65(4):1021-1029.
15. Goldgar D. E., Easton D. F., Cannon-Albright L. A., Skolnick M. H., Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands, J Natl Cancer Inst, 1994, 86(21):1600-1608.
16. Horiuchi A., Itoh K., Shimizu M., Nakai I., Yamazaki T., Kimura K., Suzuki A., Shiozawa I., Ueda N., Konishi I., Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach, Gynecol Oncol, 2003, 88(3):309-317.
17. Fujita M., Enomoto T., Yoshino K., Nomura T., Buzard G. S., Inoue M., Okudaira Y., Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer, Int J Cancer, 1995, 64(6):361-366.
18. Scully R., Chen J., Plug A., Xiao Y., Weaver D., Feunteun J., Ashley T., Livingston D. M., Association of BRCA1 with Rad51 in mitotic and meiotic cells, Cell, 1997, 88(2):265-275.
19. Sharan S. K., Morimatsu M., Albrecht U., Lim D. S., Regel E., Dinh C., Sands A., Eichele G., Hasty P., Bradley A., Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2, Nature, 1997, 386(6627):804-810.
20. Shih H. A., Couch F. J., Nathanson K. L., Blackwood M. A., Rebbeck T. R., Armstrong K. A., Calzone K., Stopfer J., Seal S., Stratton M. R., Weber B. L., BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic, J Clin Oncol, 2002, 20(4):994-999.
21. Peelen T., van Vliet M., Petrij-Bosch A., Mieremet R., Szabo C., van den Ouweland A. M., Hogervorst F., Brohet R., Ligtenberg M. J., Teugels E., van der Luijt R, van der Hout A. H., Gille J. J., Pals G., Jedema I., Olmer R., van Leeuwen I., Newman B., Plandsoen M., van der Est M., Brink G., Hageman S., Arts P. J., Bakker M. M., Devilee P., A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families, Am J Hum Genet, 1997, 60(5):1041-1049.
22. Carcangiu M. L., Radice P., Spatti G., et al., Incidental tumors in prophylactic oophorectomy specimens from BRCA mutation carriers, Modern Pathol, 2003, 16:184A.
23. Chang-Claude J., Dong J., Schimdt S., Shayeghi M., Komitowski D., Becher H., Stratton M. R., RoyerPokora B., Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes, J Med Genet, 1998, 35(2):116-121.
24. Diebold J., Phenotype-genotype-correlation in ovarian neoplasia, Verh Dtsch Ges Pathol, 2001, 85:153-160.
25. Piver M. S., Jishi M. F., Tsukada Y., Nava G., Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry, Cancer, 1993, 71(9):2751-2755.
26. Schildkraut J. M., Thompson W. D., Familial ovarian cancer: a population-based case control study, Am J Epidemiol, 1988, 128(3):456-466.
27. Berrino F., Capocaccia R., Estève J., Gatta G., Hakulinen T., Micheli A., Sant M., Verdecchia A., Survival of cancer patients in Europe: The EUROCARE-2 Study, IARC Scientific Publications No. 151, International Agency for Research on Cancer, Lyon, 1999.
28. Gras E., Catasus L., Argüelles R., Moreno-Bueno G., Palacios J., Gamallo C., Matias-Guiu X., Prat J., Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors, Cancer, 2001, 92(11):2829-2836.
29. Tropè C., Kaern J., Management of borderline tumors of the ovary: state of the art, Semin Oncol, 1998, 25(3):372-380.
30. Vine M. F., Ness R. B., Calingaert B., Schildkraut J. M., Berchuck A., Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor, Gynecol Oncol, 2001, 83(3):466-471.
31. Singer G., Shih Ie. M., Truskinovsky A., Umudum H., Kurman R. J., Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor), Int J Gynecol Pathol, 2003, 22(1):37-41.
32. Slomowitz B. M., Caputo T. A., Gretz H. F. 3rd, Economos K., Tortoriello D. V., Schlosshauer P. W., Baergen R. N., Isacson C., Soslow R. A., A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component, Am J Surg Pathol, 2002, 26(5):592-600.
33. Staebler A., Heselmeyer-Haddad K., Bell K., Riopel M., Perlman E., Ried T., Kurman R. J., Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas, Hum Pathol, 2002, 33(1):47-59.
34. Bell K. A., Smith Sehdev A. E., Kurman R. J., Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas, Am J Surg Pathol, 2001, 25(4):419-432.
35. de Nictolis M., Montironi R., Tommasoni S., Carinelli S., Ojeda B., Matías-Guiu X., Prat J., Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases, Cancer, 1992, 70(1):152-160.
36. Goff B. A., Mandel L., Muntz H. G., Melancom C. H., Ovarian carcinoma diagnosis, Cancer, 2000, 89(10):2069-2075.
37. Takeshima Y., Amatya V. J., Daimaru Y., Nakayori F., Nakano T., Inai K., Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection, Hum Pathol, 2001, 32(11):1203-1208.
38. Gaudas J. M., Li T., Nguyen H., Jensen D., Rauscher F. J. 3rd, Cowan K. H., Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells, Cell Growth Differ, 1996, 7(6):717-723.
39. Gras E., Cortes J., Diez O., Alonso C., Matias-Guiu X., Baiget M., Prat J., Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors, Cancer, 2001, 92(4):787-795.
40. Feeley K. M., Wells M., Precursor lesions of ovarian epithelial malignancy, Histopathology, 2001, 38(2):87-95.
41. Hauptmann S., Dietel M., Serous tumors of low malignant potential of the ovary-molecular pathology: part 2, Virchows Arch, 2001, 438(6):539-551.
42. Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., Tucker M. A., The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazy Jews, N Engl J Med, 1997, 336(20):1401-1408.
43. Hsu S. M., Raine L., Fanger H., Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures, J Histochem Cytochem, 1981, 29(4):577-580.
44. Jóhannsson O. T., Ranstam J., Borg A., Olsson H., Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden, 1998, 16(2):397-404.
45. Kinzler K. W., Vogelstein B., The genetic basis of human cancer, McGraw-Hill, Toronto, 1998.
46. Thompson D., Easton D., and Breast Cancer Linkage Consortium, Variations in cancer risks, by mutation position, in BRCA2 mutations carriers, Am J Hum Genet, 2001, 68(2):410-419.
47. Hall J. M., Lee M. K., Newman B., Morrow J. E., Anderson L. A., Huey B,. King M. C., Linkage of earlyonset familial breast cancer to chromosome 17q21, Science, 1990, 250(4988):1684-1689.
48. Kleppe K., Ohtsuka E., Kleppe R., Molineux I., Khorana H. G., Studies on polynucleotides. XCVI. Repair replications of short synthetic DNA's as catalyzed by DNA polymerases, J Mol Biol, 1971, 56(2):341-361.
49. Shaw P. A., McLaughlin J. R., Zweemer R. P., Narod S. A., Risch H., Verheijen R. H., Ryan A., Menko F. H., Kenemans P., Jacobs I. J., Histopathologic features of genetically determined ovarian cancer, Int J Gynecol Pathol, 2002, 21(4):407-411.
50. Vine M. F., Ness R. B., Calingaert B., Schildkraut J. M., Berchuck A., Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor, Gynecol Oncol, 2001, 83(3):466-471.
51. Deavers M. T., Gershenson D. M., Tortolero-Luna G., Malpica A., Lu K. H., Silva E. G., Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases, Am J Surg Pathol, 2002, 26(9):1129-1141.
52. Halperin R., Zehavi S., Dar P., Habler L., Hadas E., Bukovsky I., Schneider D., Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas, Eur J Gynaecol Oncol, 2001, 22(4):292-296.
53. Hamm B., Kubik-Huch R. A., Fleige B., MR imaging and CT of the female pelvis: radiologic-pathologic correlation, Eur Radiol, 1999, 9(1):3-15.
54. Struewing J. P., Watson P., Easton D. F., Ponder B. A., Lynch H. T., Tucker M. A., Prophylactic oophorectomy in inherited breast/ovarian cancer families, J Natl Cancer Inst Monogr, 1995, (17):33-35.
55. Thompson M. E., Jensen R. A., Obermiller P. S., Page D. L., Holt J. T., Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression, Nat Genet, 1995, 9(4):444-450.
56. Behrens P., Rothe M., Florin A., Wellmann A., Wernert N., Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression, Int J Mol Med, 2001, 8(2):149-154.
57. Mullis K. B., Faloona F. A., Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction, Methods Enzymol, 1987, 155:335-350.
58. Gilks C. B., Bell D. A., Scully R. E., Serous psammocarcinoma of the ovary and peritoneum, Int J Gynecol Pathol, 1990, 9(2):110-121.
59. Agoff S. N., Mendelin J. E., Grieco V. S., Garcia R. L., Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or-2 mutations: implications for gross examination, cytology and clinical follow-up, Am J Surg Pathol, 2002, 26(2):171-178.
60. Tobacman J. K., Greene M. H., Tucker M. A., Costa J., Kase R., Fraumeni J. F. Jr, Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families, Lancet, 1982, 2(8302):795-797.
61. Shih Ie. M., Kurman R. J., Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis, Am J Pathol, 2004, 164(5):1511-1518.
62. Singer G., Kurman R. J., Chang H. W., Cho S. K., Shih Ie. M., Diverse tumorigenic pathways in ovarian serous carcinoma, Am J Pathol, 2002, 160(4):1223-1228.
63. Dib C., Fauré S., Fizames C., Samson D., Drouot N., Vignal A., Millasseau P., Marc S., Hazan J., Seboun E., Lathrop M., Gyapay G., Morissette J., Weissenbach J., A comprehensive genetic map of the human genome based on 5,264 microsatellites, Nature, 1996, 380(6570):152-154.
64. Cathro H. P., Stoler M. H., Expression of cytokeratins 7 and 20 in ovarian neoplasia, Am J Clin Pathol, 2002, 117(6):944-951.
65. Vaughn J. P., Cirisano F. D., Huper G., Berchuck A., Futreal P. A., Marks J. R., Iglehart J. D., Cell cycle control of BRCA2, Cancer Res, 1996, 56(20):4590-4594.
66. Wong A. K., Pero R., Ormonde P. A., Tavtigian S. V., Bartel P. L., RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2, J Biol Chem, 1997, 272(51):31941-31944.
67. Rajan J. V., Wang M., Marquis S. T., Chodosh L. A., Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells, Proc Natl Acad Sci USA, 1996, 93(23):13078-13083.
68. Werness B. A., Ramus S. J., Whittemore A. S., Garlinghouse-Jones K, Oakley-Girvan I., Dicioccio R A., Tsukada Y., Ponder B. A., Piver M. S., Histopathology of familial ovarian tumors in women from families with and without germ-line BRCA1 mutations, Hum Pathol, 2000, 31(11):1420-1424.
69. Wooster R., Neuhausen S. L., Mangion J., Quirk Y., Ford D., Collins N., Nguyen K., Seal S., Tran T., Averill D., et al., Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13, Science, 1994, 265(5181):2088-2090.
70. Blackwood M. A., Weber B. L., BRCA1 and BRCA2: from molecular genetics to clinical medicine, J Clin Oncol, 1998, 16(5):1969-1977.
71. Chapman M. S., Verma I. M., Transcriptional activation by BRCA1, Nature, 1996, 382(6593):678-679.
72. Ouchi T., Monteiro A. N., August A., Aaronson S. A., Hanafusa H., BRCA1 regulates p53-dependent gene expression, Proc Natl Acad Sci, 1998, 95(5):2302-2306.